aah pharmaceuticals limited
aah pharmaceuticals limited Company Information
Company Number
00123458
Website
www.aah.co.ukRegistered Address
the woods haywood road, warwick, CV34 5AH
Industry
Wholesale of pharmaceutical goods
Manufacture of basic pharmaceutical products
Telephone
02476432628
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
admenta uk limited 100%
aah pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of AAH PHARMACEUTICALS LIMITED at £4.2b based on a Turnover of £3.4b and 1.23x industry multiple (adjusted for size and gross margin).
aah pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of AAH PHARMACEUTICALS LIMITED at £305.9m based on an EBITDA of £46.3m and a 6.6x industry multiple (adjusted for size and gross margin).
aah pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of AAH PHARMACEUTICALS LIMITED at £1.2b based on Net Assets of £519.2m and 2.31x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Aah Pharmaceuticals Limited Overview
Aah Pharmaceuticals Limited is a live company located in warwick, CV34 5AH with a Companies House number of 00123458. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in July 1912, it's largest shareholder is admenta uk limited with a 100% stake. Aah Pharmaceuticals Limited is a mature, mega sized company, Pomanda has estimated its turnover at £3.4b with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Aah Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Aah Pharmaceuticals Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 7 measures and has 5 areas for improvement. Company Health Check FAQs
7 Strong
0 Regular
5 Weak
Size
annual sales of £3.4b, make it larger than the average company (£26.8m)
£3.4b - Aah Pharmaceuticals Limited
£26.8m - Industry AVG
Growth
3 year (CAGR) sales growth of -2%, show it is growing at a slower rate (4.7%)
-2% - Aah Pharmaceuticals Limited
4.7% - Industry AVG
Production
with a gross margin of 7.5%, this company has a higher cost of product (30.9%)
7.5% - Aah Pharmaceuticals Limited
30.9% - Industry AVG
Profitability
an operating margin of 0.7% make it less profitable than the average company (5.3%)
0.7% - Aah Pharmaceuticals Limited
5.3% - Industry AVG
Employees
with 2801 employees, this is above the industry average (85)
2801 - Aah Pharmaceuticals Limited
85 - Industry AVG
Pay Structure
on an average salary of £34.8k, the company has a lower pay structure (£60.1k)
£34.8k - Aah Pharmaceuticals Limited
£60.1k - Industry AVG
Efficiency
resulting in sales per employee of £1.2m, this is more efficient (£442.6k)
£1.2m - Aah Pharmaceuticals Limited
£442.6k - Industry AVG
Debtor Days
it gets paid by customers after 39 days, this is earlier than average (60 days)
39 days - Aah Pharmaceuticals Limited
60 days - Industry AVG
Creditor Days
its suppliers are paid after 65 days, this is slower than average (35 days)
65 days - Aah Pharmaceuticals Limited
35 days - Industry AVG
Stock Days
it holds stock equivalent to 24 days, this is less than average (77 days)
24 days - Aah Pharmaceuticals Limited
77 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 1 weeks, this is less cash available to meet short term requirements (11 weeks)
1 weeks - Aah Pharmaceuticals Limited
11 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 63.1%, this is a higher level of debt than the average (50.7%)
63.1% - Aah Pharmaceuticals Limited
50.7% - Industry AVG
AAH PHARMACEUTICALS LIMITED financials
Aah Pharmaceuticals Limited's latest turnover from March 2023 is £3.4 billion and the company has net assets of £519.2 million. According to their latest financial statements, Aah Pharmaceuticals Limited has 2,801 employees and maintains cash reserves of £27.6 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 3,382,586,000 | 3,554,206,000 | 3,278,990,000 | 3,566,006,000 | 3,404,593,000 | 3,448,301,000 | 3,288,490,000 | 3,246,554,000 | 3,653,265,000 | 2,691,055,000 | 2,603,766,000 | 2,828,972,000 | 2,995,858,000 | 3,117,830,000 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 3,129,398,000 | 3,306,648,000 | 3,047,876,000 | 3,292,820,000 | 3,134,043,000 | 3,164,753,000 | 3,027,921,000 | 2,972,354,000 | 3,317,452,000 | 2,430,600,000 | 2,361,486,000 | 2,631,461,000 | 2,790,873,000 | 2,901,505,000 |
| Gross Profit | 253,188,000 | 247,558,000 | 231,114,000 | 273,186,000 | 270,550,000 | 283,548,000 | 260,569,000 | 274,200,000 | 335,813,000 | 260,455,000 | 242,280,000 | 197,511,000 | 204,985,000 | 216,325,000 |
| Admin Expenses | 228,707,000 | 188,136,000 | 165,660,000 | 205,005,000 | 174,716,000 | 167,725,000 | 141,924,000 | 136,716,000 | 152,123,000 | 125,930,000 | 134,867,000 | 131,765,000 | 130,159,000 | 134,631,000 |
| Operating Profit | 24,481,000 | 59,422,000 | 65,454,000 | 68,181,000 | 95,834,000 | 115,823,000 | 118,645,000 | 137,484,000 | 183,690,000 | 134,525,000 | 107,413,000 | 65,746,000 | 74,826,000 | 81,694,000 |
| Interest Payable | 13,884,000 | 923,000 | 1,602,000 | 1,374,000 | 117,000 | 241,000 | 268,000 | 4,432,000 | 6,708,000 | 668,000 | 768,000 | 33,913,000 | 746,000 | 5,766,000 |
| Interest Receivable | 23,896,000 | 3,803,000 | 13,352,000 | 13,565,000 | 11,757,000 | 18,410,000 | 16,672,000 | 23,679,000 | 53,295,000 | 45,431,000 | 37,783,000 | 1,507,000 | 32,034,000 | 36,016,000 |
| Pre-Tax Profit | 34,493,000 | 62,302,000 | 77,204,000 | 80,372,000 | 107,474,000 | 133,992,000 | 135,049,000 | 156,749,000 | 230,277,000 | 179,288,000 | 144,428,000 | 98,152,000 | 106,114,000 | 111,662,000 |
| Tax | 20,791,000 | -13,446,000 | -16,502,000 | -19,903,000 | -21,232,000 | -23,655,000 | -26,168,000 | -31,692,000 | -11,478,000 | -40,095,000 | -35,696,000 | -26,090,000 | -30,086,000 | -30,867,000 |
| Profit After Tax | 55,284,000 | 48,856,000 | 60,702,000 | 60,469,000 | 86,242,000 | 110,337,000 | 108,881,000 | 125,057,000 | 218,799,000 | 139,193,000 | 108,732,000 | 72,062,000 | 76,028,000 | 80,795,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 300,000,000 | 0 | 0 | 635,000,000 | 110,000,000 | 130,000,000 | 60,000,000 | 50,000,000 | 50,000,000 |
| Retained Profit | 55,284,000 | 48,856,000 | 60,702,000 | 60,469,000 | 86,242,000 | -189,663,000 | 108,881,000 | 125,057,000 | -416,201,000 | 29,193,000 | -21,365,000 | 10,899,000 | 26,028,000 | 30,795,000 |
| Employee Costs | 97,554,000 | 94,694,000 | 99,541,000 | 105,136,000 | 94,940,000 | 88,221,000 | 74,457,000 | 75,457,000 | 89,194,000 | 72,521,000 | 75,959,000 | 74,363,000 | 74,506,000 | 72,134,000 |
| Number Of Employees | 2,801 | 2,628 | 2,888 | 3,005 | 3,032 | 2,989 | 2,744 | 2,770 | 2,790 | 2,834 | 2,964 | 3,141 | 3,333 | 3,356 |
| EBITDA* | 46,329,000 | 82,179,000 | 89,723,000 | 93,780,000 | 103,712,000 | 122,594,000 | 124,455,000 | 143,200,000 | 193,981,000 | 139,513,000 | 112,304,000 | 71,474,000 | 79,935,000 | 87,236,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 71,554,000 | 238,613,000 | 246,471,000 | 126,748,000 | 98,374,000 | 102,807,000 | 103,318,000 | 36,903,000 | 33,667,000 | 36,967,000 | 30,198,000 | 34,053,000 | 28,120,000 | 28,961,000 |
| Intangible Assets | 4,345,000 | 4,345,000 | 4,345,000 | 4,345,000 | 0 | 0 | 0 | 0 | 431,000 | 195,000 | 2,818,000 | 2,069,000 | 0 | 0 |
| Investments & Other | 16,373,000 | 26,172,000 | 27,100,000 | 22,114,000 | 52,359,000 | 59,899,000 | 72,278,000 | 9,134,000 | 4,540,000 | 8,842,000 | 52,000 | 1,604,000 | 1,636,000 | 1,752,000 |
| Debtors (Due After 1 year) | 10,029,000 | 138,180,000 | 139,713,000 | 4,592,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 102,301,000 | 242,431,000 | 248,756,000 | 131,093,000 | 98,374,000 | 102,807,000 | 103,318,000 | 36,903,000 | 34,098,000 | 37,162,000 | 33,016,000 | 36,122,000 | 28,120,000 | 28,961,000 |
| Stock & work in progress | 209,013,000 | 234,419,000 | 228,501,000 | 208,593,000 | 259,545,000 | 195,083,000 | 229,034,000 | 191,451,000 | 184,793,000 | 168,912,000 | 165,448,000 | 213,093,000 | 202,160,000 | 218,049,000 |
| Trade Debtors | 365,852,000 | 251,398,000 | 290,583,000 | 323,680,000 | 407,199,000 | 428,194,000 | 440,714,000 | 457,258,000 | 517,286,000 | 389,276,000 | 403,207,000 | 396,417,000 | 434,525,000 | 470,899,000 |
| Group Debtors | 616,153,000 | 115,413,000 | 141,394,000 | 291,540,000 | 0 | 0 | 139,519,000 | 0 | 0 | 517,349,000 | 362,115,000 | 406,083,000 | 396,472,000 | 413,349,000 |
| Misc Debtors | 85,420,000 | 97,548,000 | 120,594,000 | 124,474,000 | 117,323,000 | 62,389,000 | 82,161,000 | 54,349,000 | 9,724,000 | 29,478,000 | 49,202,000 | 55,562,000 | 60,959,000 | 86,623,000 |
| Cash | 27,555,000 | 192,071,000 | 154,759,000 | 120,968,000 | 268,658,000 | 210,316,000 | 2,765,000 | 205,608,000 | 53,613,000 | 10,000 | 33,213,000 | 1,424,000 | 5,507,000 | 9,630,000 |
| misc current assets | 0 | 319,000 | 243,000 | 410,000 | 131,000 | 263,000 | 1,215,000 | 3,249,000 | 1,998,000 | 3,609,000 | 94,000 | 1,000 | 227,000 | 40,000 |
| total current assets | 1,303,993,000 | 891,168,000 | 936,074,000 | 1,069,665,000 | 1,052,856,000 | 896,245,000 | 895,408,000 | 911,915,000 | 767,414,000 | 1,108,634,000 | 1,013,279,000 | 1,072,580,000 | 1,099,850,000 | 1,198,590,000 |
| total assets | 1,406,294,000 | 1,133,599,000 | 1,184,830,000 | 1,200,758,000 | 1,151,230,000 | 999,052,000 | 998,726,000 | 948,818,000 | 801,512,000 | 1,145,796,000 | 1,046,295,000 | 1,108,702,000 | 1,127,970,000 | 1,227,551,000 |
| Bank overdraft | 0 | 0 | 1,870,000 | 0 | 0 | 0 | 8,832,000 | 0 | 75,000 | 30,664,000 | 0 | 34,271,000 | 76,123,000 | 210,210,000 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 562,658,000 | 459,073,000 | 587,780,000 | 655,522,000 | 628,790,000 | 487,951,000 | 486,037,000 | 476,741,000 | 486,566,000 | 380,629,000 | 333,225,000 | 346,082,000 | 352,549,000 | 334,524,000 |
| Group/Directors Accounts | 112,355,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 181,000 | 171,000 | 39,000 | 15,000 | 153,000 | 0 | 0 | 0 | 0 | 0 | 0 | 47,000 |
| hp & lease commitments | 10,457,000 | 11,784,000 | 11,676,000 | 13,334,000 | 0 | 0 | 0 | 0 | 48,000 | 162,000 | 186,000 | 259,000 | 266,000 | 210,000 |
| other current liabilities | 34,636,000 | 154,235,000 | 126,018,000 | 131,514,000 | 228,727,000 | 302,316,000 | 105,997,000 | 130,094,000 | 101,038,000 | 98,842,000 | 97,874,000 | 85,730,000 | 69,730,000 | 74,744,000 |
| total current liabilities | 720,106,000 | 625,092,000 | 727,525,000 | 800,541,000 | 857,556,000 | 790,282,000 | 601,019,000 | 606,835,000 | 587,727,000 | 510,297,000 | 431,285,000 | 466,342,000 | 498,668,000 | 619,735,000 |
| loans | 131,750,000 | 64,302,000 | 63,454,000 | 82,090,000 | 0 | 0 | 0 | 0 | 6,000 | 184,000 | 396,000 | 784,000 | 404,000 | 586,000 |
| hp & lease commitments | 31,888,000 | 32,151,000 | 31,727,000 | 41,045,000 | 0 | 0 | 0 | 0 | 3,000 | 92,000 | 198,000 | 392,000 | 202,000 | 293,000 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 3,394,000 | 13,066,000 | 12,596,000 | 27,724,000 | 16,346,000 | 9,944,000 | 3,208,000 | 4,916,000 | 6,630,000 | 13,788,000 | 27,642,000 | 33,472,000 | 15,550,000 | 24,792,000 |
| total long term liabilities | 167,032,000 | 38,684,000 | 38,025,000 | 54,907,000 | 8,173,000 | 4,972,000 | 1,604,000 | 2,458,000 | 3,318,000 | 6,986,000 | 14,019,000 | 17,128,000 | 7,977,000 | 12,689,000 |
| total liabilities | 887,138,000 | 663,776,000 | 765,550,000 | 855,448,000 | 865,729,000 | 795,254,000 | 602,623,000 | 609,293,000 | 591,045,000 | 517,283,000 | 445,304,000 | 483,470,000 | 506,645,000 | 632,424,000 |
| net assets | 519,156,000 | 469,823,000 | 419,280,000 | 345,310,000 | 285,501,000 | 203,798,000 | 396,103,000 | 339,525,000 | 210,467,000 | 628,513,000 | 600,991,000 | 625,232,000 | 621,325,000 | 595,127,000 |
| total shareholders funds | 519,156,000 | 469,823,000 | 419,280,000 | 345,310,000 | 285,501,000 | 203,798,000 | 396,103,000 | 339,525,000 | 210,467,000 | 628,513,000 | 600,991,000 | 625,232,000 | 621,325,000 | 595,127,000 |
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 24,481,000 | 59,422,000 | 65,454,000 | 68,181,000 | 95,834,000 | 115,823,000 | 118,645,000 | 137,484,000 | 183,690,000 | 134,525,000 | 107,413,000 | 65,746,000 | 74,826,000 | 81,694,000 |
| Depreciation | 21,848,000 | 22,757,000 | 24,269,000 | 25,599,000 | 7,878,000 | 6,771,000 | 5,810,000 | 5,716,000 | 7,473,000 | 4,988,000 | 4,891,000 | 5,307,000 | 5,109,000 | 5,542,000 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,818,000 | 0 | 0 | 421,000 | 0 | 0 |
| Tax | 20,791,000 | -13,446,000 | -16,502,000 | -19,903,000 | -21,232,000 | -23,655,000 | -26,168,000 | -31,692,000 | -11,478,000 | -40,095,000 | -35,696,000 | -26,090,000 | -30,086,000 | -30,867,000 |
| Stock | -25,406,000 | 5,918,000 | 19,908,000 | -50,952,000 | 64,462,000 | -33,951,000 | 37,583,000 | 6,658,000 | 184,793,000 | 3,464,000 | -47,645,000 | 10,933,000 | -15,889,000 | 218,049,000 |
| Debtors | 474,915,000 | -89,745,000 | -52,002,000 | 219,764,000 | 33,939,000 | -171,811,000 | 150,787,000 | -15,403,000 | 527,010,000 | 121,579,000 | -43,538,000 | -33,894,000 | -78,915,000 | 970,871,000 |
| Creditors | 103,585,000 | -128,707,000 | -67,742,000 | 26,732,000 | 140,839,000 | 1,914,000 | 9,296,000 | -9,825,000 | 486,566,000 | 47,404,000 | -12,857,000 | -6,467,000 | 18,025,000 | 334,524,000 |
| Accruals and Deferred Income | -119,599,000 | 28,217,000 | -5,496,000 | -97,213,000 | -73,589,000 | 196,319,000 | -24,097,000 | 29,056,000 | 101,038,000 | 968,000 | 12,144,000 | 16,000,000 | -5,014,000 | 74,744,000 |
| Deferred Taxes & Provisions | -9,672,000 | 470,000 | -15,128,000 | 11,378,000 | 6,402,000 | 6,736,000 | -1,708,000 | -1,714,000 | 6,630,000 | -13,854,000 | -5,830,000 | 17,922,000 | -9,242,000 | 24,792,000 |
| Cash flow from operations | -408,075,000 | 52,540,000 | 16,949,000 | -154,038,000 | 57,731,000 | 509,670,000 | -106,592,000 | 137,770,000 | 64,934,000 | 8,893,000 | 161,248,000 | 95,800,000 | 148,422,000 | -698,491,000 |
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | -9,799,000 | -928,000 | 4,986,000 | -30,245,000 | -7,540,000 | -12,379,000 | 63,144,000 | 4,594,000 | 4,540,000 | 8,790,000 | -1,552,000 | -32,000 | -116,000 | 1,752,000 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 112,355,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | -181,000 | 10,000 | 132,000 | 24,000 | -138,000 | 153,000 | 0 | 0 | 0 | 0 | 0 | -47,000 | 47,000 |
| Long term loans | 67,448,000 | 848,000 | -18,636,000 | 82,090,000 | 0 | 0 | 0 | -6,000 | 6,000 | -212,000 | -388,000 | 380,000 | -182,000 | 586,000 |
| Hire Purchase and Lease Commitments | -1,590,000 | 532,000 | -10,976,000 | 54,379,000 | 0 | 0 | 0 | -51,000 | 51,000 | -130,000 | -267,000 | 183,000 | -35,000 | 503,000 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 10,012,000 | 2,880,000 | 11,750,000 | 12,191,000 | 11,640,000 | 18,169,000 | 16,404,000 | 19,247,000 | 46,587,000 | 44,763,000 | 37,015,000 | -32,406,000 | 31,288,000 | 30,250,000 |
| cash flow from financing | 182,274,000 | 5,766,000 | -4,584,000 | 148,132,000 | 7,125,000 | 15,389,000 | -35,746,000 | 23,191,000 | 673,312,000 | 42,750,000 | 33,484,000 | -38,835,000 | 31,194,000 | 595,718,000 |
| cash and cash equivalents | ||||||||||||||
| cash | -164,516,000 | 37,312,000 | 33,791,000 | -147,690,000 | 58,342,000 | 207,551,000 | -202,843,000 | 151,995,000 | 53,613,000 | -33,203,000 | 31,789,000 | -4,083,000 | -4,123,000 | 9,630,000 |
| overdraft | 0 | -1,870,000 | 1,870,000 | 0 | 0 | -8,832,000 | 8,832,000 | -75,000 | 75,000 | 30,664,000 | -34,271,000 | -41,852,000 | -134,087,000 | 210,210,000 |
| change in cash | -164,516,000 | 39,182,000 | 31,921,000 | -147,690,000 | 58,342,000 | 216,383,000 | -211,675,000 | 152,070,000 | 53,538,000 | -63,867,000 | 66,060,000 | 37,769,000 | 129,964,000 | -200,580,000 |
aah pharmaceuticals limited Credit Report and Business Information
Aah Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for aah pharmaceuticals limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other mega companies, companies in CV34 area or any other competitors across 12 key performance metrics.
aah pharmaceuticals limited Ownership
AAH PHARMACEUTICALS LIMITED group structure
Aah Pharmaceuticals Limited has 4 subsidiary companies.
Ultimate parent company
AURELIUS INVESTMENT LUX ONE SARL
#0143598
2 parents
AAH PHARMACEUTICALS LIMITED
00123458
4 subsidiaries
aah pharmaceuticals limited directors
Aah Pharmaceuticals Limited currently has 4 directors. The longest serving directors include Ms Wendy Hall (Jul 2022) and Mrs Wendy Hall (Jul 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Ms Wendy Hall | England | 54 years | Jul 2022 | - | Director |
| Mrs Wendy Hall | 54 years | Jul 2022 | - | Director | |
| Mr David Bound | England | 62 years | Dec 2022 | - | Director |
| Mr Adrian Stubbings | England | 51 years | Feb 2024 | - | Director |
P&L
March 2023turnover
3.4b
-5%
operating profit
24.5m
-59%
gross margin
7.5%
+7.46%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
519.2m
+0.11%
total assets
1.4b
+0.24%
cash
27.6m
-0.86%
net assets
Total assets minus all liabilities
aah pharmaceuticals limited company details
company number
00123458
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
21100 - Manufacture of basic pharmaceutical products
incorporation date
July 1912
age
112
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2023
previous names
mawson & proctor pharmaceuticals limited (April 1987)
accountant
-
auditor
DELIOTTE LLP
address
the woods haywood road, warwick, CV34 5AH
Bank
LLOYDS TSB BANK PLC
Legal Advisor
-
aah pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 12 charges/mortgages relating to aah pharmaceuticals limited. Currently there are 7 open charges and 5 have been satisfied in the past.
aah pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
